Marinomed Biotech AG announces results for the first half year of 2025
Ad-hoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 61.607 no-par value bearer shares at an issue price of EUR 17,50 per share
Ad-hoc: Marinomed Biotech AG: Agreement on the key terms of the issue of a secured EUR 2.5mn convertible bond
Marinomed Biotech AG announces partnership for Budesolv in Switzerland
Public Relations